{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(6)"],"submitter":["Alsoud LO"],"pubmed_abstract":["Metabolic syndrome (MetS) is a disorder characterized by a group of factors that can increase the risk of chronic diseases, including cardiovascular diseases and type 2 diabetes mellitus (T2D). Metabolomics has provided new insight into disease diagnosis and biomarker identification. This cross-sectional investigation used an untargeted metabolomics-based technique to uncover metabolomic alterations and their relationship to pathways in normoglycemic and prediabetic MetS participants to improve disease diagnosis. Plasma samples were collected from drug-naive prediabetic MetS patients (<i>n</i> = 26), normoglycemic MetS patients (<i>n</i> = 30), and healthy (normoglycemic lean) subjects (<i>n</i> = 30) who met the inclusion criteria for the study. The plasma samples were analyzed using high"],"journal":["Metabolites"],"pagination":["508"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9227428"],"repository":["biostudies-literature"],"pubmed_title":["Identification of Insulin Resistance Biomarkers in Metabolic Syndrome Detected by UHPLC-ESI-QTOF-MS."],"pmcid":["PMC9227428"],"pubmed_authors":["Kasabri V","Soares NC","Al-Hroub HM","Alzoubi KH","Suyagh M","Semreen MH","El-Huneidi W","Alsoud LO","Bulatova N","Abu-Irmaileh B","Bustanji Y","Mousa M"],"additional_accession":[]},"is_claimable":false,"name":"Identification of Insulin Resistance Biomarkers in Metabolic Syndrome Detected by UHPLC-ESI-QTOF-MS.","description":"Metabolic syndrome (MetS) is a disorder characterized by a group of factors that can increase the risk of chronic diseases, including cardiovascular diseases and type 2 diabetes mellitus (T2D). Metabolomics has provided new insight into disease diagnosis and biomarker identification. This cross-sectional investigation used an untargeted metabolomics-based technique to uncover metabolomic alterations and their relationship to pathways in normoglycemic and prediabetic MetS participants to improve disease diagnosis. Plasma samples were collected from drug-naive prediabetic MetS patients (<i>n</i> = 26), normoglycemic MetS patients (<i>n</i> = 30), and healthy (normoglycemic lean) subjects (<i>n</i> = 30) who met the inclusion criteria for the study. The plasma samples were analyzed using high","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-05T13:34:16.943Z","creation":"2025-04-05T13:34:16.943Z"},"accession":"S-EPMC9227428","cross_references":{"pubmed":["35736441"],"doi":["10.3390/metabo12060508"]}}